View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/CMS | RIN: 0938-AT91 | Publication ID: Fall 2020 |
Title: International Pricing Index Model For Medicare Part B Drugs (CMS-5528)(Section 610 Review) | |
Abstract:
This rule finalizes testing changes to payment for certain separately payable Part B drugs and biologicals. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Economically Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: Yes | Unfunded Mandates: No |
EO 13771 Designation: Regulatory | |
RFA Section 610 Review: Section 610 Review | |
CFR Citation: 42 CFR 513 | |
Legal Authority: Social Security Act, sec. 1115A |
Legal Deadline:
|
|||||||||||||||||||||
Overall Description of Deadline: Per the CMS notice published December 30, 2004 (69 FR 78442), except for certain Medicare payment regulations and certain other statutorily-mandated regulations, we schedule all Medicare final regulations for publication within the 3-year standardized time limit in the current Unified Agenda. We do not intend to delay publishing a Medicare final regulation for 3 years if we are able to publish it sooner. |
|||||||||||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Yes | Government Levels Affected: Federal, State |
Small Entities Affected: Businesses | Federalism: No |
Included in the Regulatory Plan: No | |
International Impacts: This regulatory action will be likely to have international trade and investment effects, or otherwise be of international interest. | |
RIN Data Printed in the FR: Yes | |
Agency Contact: Andrew York Social Science Research Analyst Department of Health and Human Services Centers for Medicare & Medicaid Services Center for Medicare and Medicaid Innovation, MS: WB-06-05, 7500 Security Boulevard, Baltimore, MD 21244 Phone:410 786-8945 Email: andrew.york1@cms.hhs.gov |